EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model

Erica Acquarone iD, Steve B Garcia Gutierrez, Hong Zhang, Alexander Morin, Maria Maccecchini, Ottavio Arancio

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-10 · 12 (4)

DOI: 10.1002/trc2.70336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 28.10.2026. Verfasst von Erica Acquarone und 5 weiteren Autor:innen. Beteiligte Einrichtung: Taub Institute for Research on Alzheimer's Disease and the Aging Brain New York New York USA. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Alzheimer's disease (AD) results from disruptions in proteostasis, metabolism, and neurotrophic signaling that impair synaptic plasticity and memory. Dulaglutide, a blood–brain barrier (BBB)‐permeant glucagon‐like peptide‐1 (GLP‐1) receptor agonist, enhances phosphoinositide 3‐kinase (PI3K)/Akt and cAMP response element‐binding protein (CREB) signaling, while buntanetap reduces translation of aggregation‐prone proteins such as amyloid precursor protein (APP), tau, α‐synuclein, and transactive response DNA‐binding protein of 43 kDa. Although both compounds show cognitive benefits individually, their potential synergistic effects remain unexplored. METHODS APP/presenilin 1 (PS1) mice and wild‐type (WT) littermates were treated with dulaglutide or buntanetap at high or subthreshold doses, alone or in combination, beginning at plaque deposition. Spatial memory was assessed through the 2‐day radial arm water maze (RAWM), associative memory using contextual fear conditioning, and hippocampal Schaffer collateral–CA1 long‐term potentiation (LTP) was evaluated as a measure of synaptic plasticity. Motor, sensory, motivational, and shock‐sensitivity controls were included to rule out confounding non‐cognitive effects. Meso Scale Discovery and Western blotting analyses were performed on frozen hippocampal tissue to assess amyloid beta (Aβ) and the postsynaptic density protein 95 (PSD95) marker levels. RESULTS High doses of either dulaglutide or buntanetap alone rescued deficits in spatial and contextual memory as well as LTP in APP/PS1 mice, whereas lower doses produced minimal or partial benefit. Concurrent administration of low, individually ineffective doses of buntanetap (1 mg/kg) and dulaglutide (0.1 mg/kg) fully rescued RAWM performance, restored contextual fear memory and CA1 LTP, reduced Aβ levels, and restored PSD95. The combination treatment did not alter behavior in WT mice across control behavioral tasks, confirming treatment specificity for AD‐related deficits. DISCUSSION Our findings demonstrate a strong synergistic interaction between BBB‐permeant dulaglutide and buntanetap at subthreshold doses, showing that combined enhancement of neurotrophic signaling and reduction of proteotoxic stress can rescue hippocampal dysfunction in early AD. This convergence between GLP‐1 receptor‐mediated pathways and inhibition of neurotoxic protein synthesis supports the clinical evaluation of GLP‐1‐based combination therapies with proteostatic modulators such as buntanetap.

Schlagwörter

Stichwörter der Autor:innen

APP/PS1 miceAlzheimer's diseaseGLP‐1 receptor agonistsblood–brain barrier permeabilitybuntanetapcognitive outcomescombination therapydisease‐modifying treatmentdulaglutidelong‐term potentiationmild cognitive impairmentneuroprotectionproteotoxic stresssynaptic plasticitytranslational relevance

Autor:innen und Institutionen

  • Taub Institute for Research on Alzheimer's Disease and the Aging Brain New York New York USA.
  • Annovis Bio Malvern Pennsylvania USA.
  • Department of Pathology and Cell Biology Columbia University New York New York USA.
  • Department of Medicine Columbia University New York New York USA.

ORCID-Profile: Erica Acquarone

Zitieren

APA

Acquarone, E., Gutierrez, S. B. G., Zhang, H., Morin, A., Maccecchini, M., & Arancio, O. (2026). Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 12(4). https://doi.org/10.1002/trc2.70336

Vancouver

Acquarone E, Gutierrez SBG, Zhang H, Morin A, Maccecchini M, Arancio O. Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026;12(4). doi:10.1002/trc2.70336

BibTeX
@article{Acquarone2026,
  author = {Acquarone, Erica and Gutierrez, Steve B Garcia and Zhang, Hong and Morin, Alexander and Maccecchini, Maria and Arancio, Ottavio},
  title = {Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2026},
  volume = {12},
  number = {4},
  doi = {10.1002/trc2.70336}
}
Kostenlos starten →